Sanofi — Director's Dealing 2016

Feb 18, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2016-02-16

Reporting Person: Sanofi (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-16	Common Stock	P	2145	$387.4283	Acquired	23194653	Indirect
2016-02-16	Common Stock	P	2196	$388.2999	Acquired	23196849	Indirect
2016-02-16	Common Stock	P	6789	$389.4759	Acquired	23203638	Indirect
2016-02-16	Common Stock	P	14303	$390.4695	Acquired	23217941	Indirect
2016-02-16	Common Stock	P	33131	$391.3591	Acquired	23251072	Indirect
2016-02-16	Common Stock	P	14692	$392.3656	Acquired	23265764	Indirect
2016-02-16	Common Stock	P	7301	$393.2723	Acquired	23273065	Indirect
2016-02-16	Common Stock	P	600	$393.95	Acquired	23273665	Indirect
2016-02-17	Common Stock	P	1507	$390.1449	Acquired	23275172	Indirect
2016-02-17	Common Stock	P	3681	$391.2307	Acquired	23278853	Indirect
2016-02-17	Common Stock	P	27088	$391.8482	Acquired	23305941	Indirect
2016-02-17	Common Stock	P	6730	$393.1577	Acquired	23312671	Indirect
2016-02-17	Common Stock	P	12988	$394.2403	Acquired	23325659	Indirect
2016-02-17	Common Stock	P	13288	$395.3203	Acquired	23338947	Indirect
2016-02-17	Common Stock	P	11018	$396.2026	Acquired	23349965	Indirect
2016-02-17	Common Stock	P	3400	$397.0707	Acquired	23353365	Indirect
2016-02-17	Common Stock	P	300	$398.38	Acquired	23353665	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").

F3: Purchase prices range from $386.74 to $387.60 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,554,113 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $387.82 to $388.73 per share, inclusive.

F6: Purchase prices range from $388.91 to $389.90 per share, inclusive.

F7: Purchase prices range from $389.95 to $390.93 per share, inclusive.

F8: Purchase prices range from $390.95 to $391.93 per share, inclusive.

F9: Purchase prices range from $391.95 to $392.94 per share, inclusive.

F10: Purchase prices range from $392.95 to $393.87 per share, inclusive.

F11: Purchase price was $393.95 per share.

F12: Purchase prices range from $389.68 to $390.52 per share, inclusive.

F13: Purchase prices range from $390.70 to $391.69 per share, inclusive.

F14: Purchase prices range from $391.73 to $392.71 per share, inclusive.

F15: Purchase prices range from $392.73 to $393.66 per share, inclusive.

F16: Purchase prices range from $393.74 to $394.72 per share, inclusive.

F17: Purchase prices range from $394.74 to $395.73 per share, inclusive.

F18: Purchase prices range from $395.75 to $396.74 per share, inclusive.

F19: Purchase prices range from $396.81 to $397.68 per share, inclusive.

F20: Purchase price was $398.38 per share.